Heart failure medication optimization study for clinicians and patients
Part of Heart & circulation clinical trials.
This study tests tools to help doctors and patients work together to start or adjust heart failure medicines. You may qualify if your heart's pumping strength is low and you are missing certain recommended medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your most recent heart imaging shows a pumping strength of 40% or less
- You have a clinic visit with an enrolled doctor within the next 7 days
- You are not already taking at least one of four key heart failure medication types (beta blockers, ARNI, aldosterone antagonists, or SGLT2 inhibitors) and have no allergy to that type
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well patients with heart failure and a weakened heart muscle (ejection fraction of 40% or lower) do when taking the recommended heart failure medications. The goal is to see if these treatments improve their heart function and quality of life.
This trial tests a digital health tool to help manage heart failure medications after you leave the hospital. If you were recently hospitalized for heart failure and have a smartphone or tablet, you may be able to join.
This study tests a personalized approach to safely increase the dose of your heart failure medication (beta-blocker). It aims to improve your symptoms and overall heart function by tailoring the dose to your specific needs.
This study tests whether patients whose heart failure has improved can safely reduce some of their medications. If your heart function has recovered significantly and stayed stable, this trial explores whether you can gradually lower doses of heart failure drugs while staying healthy.
This study tests an investigational medication called elecoglipron to see if it can improve heart and blood vessel outcomes in people with heart failure with preserved or mildly reduced ejection fraction. If you join, you will receive either the study drug or a placebo, and your heart health will be monitored over time.
This study evaluates how well doctors follow guidelines for treating heart failure with reduced ejection fraction (HFrEF). It aims to improve the quality of care you receive during your regular clinic visits over the next year.
Hear when a new Heart Failure With Reduced Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.